[
  {
    "ts": null,
    "headline": "3 Unpopular Stocks We Think Twice About",
    "summary": "Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.",
    "url": "https://finnhub.io/api/news?id=b0d62c75af8cf06e1997445b023fc527fb1467d1215ff36360c59d781768ce95",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764823055,
      "headline": "3 Unpopular Stocks We Think Twice About",
      "id": 137680187,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.",
      "url": "https://finnhub.io/api/news?id=b0d62c75af8cf06e1997445b023fc527fb1467d1215ff36360c59d781768ce95"
    }
  },
  {
    "ts": null,
    "headline": "Gilead (GILD) Valuation After Fresh Buy Rating and Extended Biktarvy Exclusivity Boost Investor Confidence",
    "summary": "Gilead Sciences (GILD) just got a confidence boost from Wall Street, with Truist initiating coverage at Buy and Mizuho flagging a longer US exclusivity window for HIV flagship Biktarvy after key litigation settlements. See our latest analysis for Gilead Sciences. The mix of upbeat HIV and oncology commentary and a longer Biktarvy exclusivity window has helped support sentiment, with a roughly 36 percent year to date share price return and a 5 year total shareholder return above 150 percent...",
    "url": "https://finnhub.io/api/news?id=cb87873affcd8899628505669ef56165d7b97e11cbdbb31643bac50b472fc3e1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764818123,
      "headline": "Gilead (GILD) Valuation After Fresh Buy Rating and Extended Biktarvy Exclusivity Boost Investor Confidence",
      "id": 137677968,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead Sciences (GILD) just got a confidence boost from Wall Street, with Truist initiating coverage at Buy and Mizuho flagging a longer US exclusivity window for HIV flagship Biktarvy after key litigation settlements. See our latest analysis for Gilead Sciences. The mix of upbeat HIV and oncology commentary and a longer Biktarvy exclusivity window has helped support sentiment, with a roughly 36 percent year to date share price return and a 5 year total shareholder return above 150 percent...",
      "url": "https://finnhub.io/api/news?id=cb87873affcd8899628505669ef56165d7b97e11cbdbb31643bac50b472fc3e1"
    }
  }
]